A new treatment for polycythemia vera: recombinant interferon alfa [see
comments]
RT Silver
Division of Hematology/Oncology, New York Hospital-Cornell Medical Center,
New York, NY 10021.
Recombinant interferon alfa, a natural product with growth inhibitory
capabilities, has been demonstrated for the first time to have significant
therapeutic efficacy in controlling the red cell mass in patients with the
myeloproliferative disease polycythemia vera. The starting dose was 3.0 X
10(6) U three times a week, subcutaneously (SC). In three patients the dose
required was 5.0 X 10(6), U five times a week, SC. Side effects were easily
tolerated. The striking advantage in the use of this drug is its presumed
absence of antileukemic effect. Further evaluation is necessary, but the
initial responses are encouraging.
Volume 76,
Issue 4,
pp. 664-665,
08/15/1990
Copyright © 1990 by The American Society of Hematology